Beiersdorf's medical division sales up 21%:
This article was originally published in Clinica
Executive Summary
Sales at the medical division of Beiersdorf (Germany) grew 21% to DM 1,063 million ($668 million) in the nine months ended September 30th. Excluding the effect of the acquisition of the Futuro brand from Kendall (see Clinica No 687, p 11), this represents sales growth of 8%. Total turnover rose 8% to DM 4,409 million compared with the same period in the previous year. The company forecasts sales growth of 8% for the full year.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.